

## Original Article

# Antibacterial activity of ondansetron and granisetron in vitro

Zhi-Qing Zou<sup>1</sup>, Xing-Gen Zhou<sup>2</sup>, Jie Wang<sup>2</sup>

<sup>1</sup>Department of Anesthesiology, Chang Zhou No.2 People's Hospital Affiliated Nanjing Medical University, Changzhou, Jiangsu Province, P.R. China; <sup>2</sup>Department of Anesthesiology, Wujiang First Hospital, Nantong University Medical School, Suzhou, P.R. China

Received August 18, 2016; Accepted November 7, 2016; Epub January 15, 2017; Published January 30, 2017

**Abstract:** To study the antibacterial activity of antiemetic drugs ondansetron and granisetron in vitro. *Escherichia coli* (*E. coli*), *Staphylococcus aureus* (*S. aureus*) and *Pseudomonas aeruginosa* (*P. aeruginosa*) were grown in medium containing 0.5 mg/mL, 0.25 mg/mL, 0.125 mg/mL and 0.0625 mg/mL ondansetron or granisetron. The number of colonies was counted after 24 hours. Normal saline was used as control. Each experiment was repeated ten times. At  $\geq 0.25$  mg/ml, ondansetron inhibits the growth of *E. coli* and *P. aeruginosa*. *S. aureus* growth was inhibited at concentration of  $\geq 0.5$  mg/ml. Granisetron inhibits *E. coli* growth beginning at 0.0625 mg/ml and growth of both *P. aeruginosa* and *S. aureus* at  $\geq 0.25$  mg/ml. Almost in all strains, there was a significant difference in the antibacterial activity between 6 and 24 h incubation times when the concentration of agents inhibited bacterial growth. We found that ondansetron and granisetron have inhibitory activity on growth of *E. coli*, *S. aureus* and *P. aeruginosa* in vitro.

**Keywords:** Ondansetron, granisetron, inhibitory activity, vitro

## Introduction

In recent years, the proportion of epidural anesthesia was very high in China, especially these patients after obstetrics and gynecology surgery under this anesthesia often selected postoperative epidural analgesia [1, 2]. Postoperative analgesia medication generally lasts more than 40 hours, leading to potential epidural infection, and the infection rate has been on the rise [3, 4].

Anti-nausea and vomiting drugs are commonly used in combination with local analgesics for postoperative epidural analgesia [5]. Previous studies have showed that commonly used local anesthetics such as lidocaine and bupivacain have a certain antibacterial effect [6-9]. Antiemetics such as ondansetron [10] and granisetron [11] are used widely as additive agents for analgesia, and because of the antibacterial activity of 5-HT uptake inhibitor, sertraline [1, 12], we hypothesis ondansetron and granisetron which are the 5-HT<sub>3</sub> serotonin antagonist may have antibacterial activity.

In the present study, we research the inhibitory effects of ondansetron and granisetron on different bacteria growth with varied agent concentrations in vitro.

## Materials and methods

The ethics committee of the Suzhou BenQ medical center approved the protocol:

### Drugs

Preservative-free ondansetron hydrochloride (2 mg/mL, Shandong Qilu Pharmaceutical, China) and granisetron hydrochloride (1 mg/mL, Suzhou Changzhen-Xinkai Pharmaceutical, China) were diluted with sterile saline to final concentrations of 1, 0.5, 0.25 and 0.125 mg/mL. Sterile saline alone was used as control.

### Bacteria strains

Standard clinical laboratory strains of *Escherichia coli* (*E. coli*) (ATCC25922), *Staphylococcus aureus* (*S. aureus*) (ATCC25923) and *Pseudo-*

## Andansetron and granisetron as antibacterial

**Table 1.** Bacterial colony numbers at different concentrations of ondansetron

Ondansetron (mg/mL)	Incubation time (hours)	E. coli (CFU/mL)	S. aureus (CFU/mL)	P. aeruginosa (CFU/mL)
1	6	$(6.3 \pm 0.6) \times 10^{5*}$	$(8.6 \pm 1.3) \times 10^{5*}$	$(1.3 \pm 0.3) \times 10^{4*}$
	24	$(3.5 \pm 1.2) \times 10^{4* \#}$	$(1.7 \pm 0.6) \times 10^{4* \#}$	$(9.0 \pm 3.4) \times 10^{2* \#}$
0.5	6	$(1.0 \pm 0.2) \times 10^{6*}$	$(3.2 \pm 1.2) \times 10^6$	$(1.3 \pm 0.1) \times 10^{5*}$
	24	$(4.6 \pm 1.9) \times 10^{5* \#}$	$(3.9 \pm 0.7) \times 10^{5* \#}$	$(1.7 \pm 0.6) \times 10^{4* \#}$
0.25	6	$(6.8 \pm 1.7) \times 10^6$	$(7.7 \pm 1.6) \times 10^6$	$(3.3 \pm 0.6) \times 10^6$
	24	$(9.8 \pm 0.9) \times 10^{5* \#}$	$(8.9 \pm 2.8) \times 10^6$	$(3.4 \pm 1.5) \times 10^6$
0.125	6	$(7.9 \pm 1.6) \times 10^6$	$(8.5 \pm 1.5) \times 10^6$	$(3.5 \pm 1.9) \times 10^6$
	24	$(8.5 \pm 2.3) \times 10^6$	$(9.0 \pm 3.6) \times 10^6$	$(7.3 \pm 1.3) \times 10^6$
0	0		$5 \times 10^6$	
	6	$(1.1 \pm 0.3) \times 10^7$	$(1.0 \pm 0.1) \times 10^7$	$(4.1 \pm 1.1) \times 10^6$
	24	$(1.3 \pm 0.4) \times 10^7$	$(3.9 \pm 0.7) \times 10^7$	$(6.5 \pm 0.6) \times 10^6$

\*P<0.01, versus bacterial cultured with 0 mg/ml for 6 hours or 24 hours correspondingly; #P<0.01, versus bacterial cultured with different drug concentrations for 6 hours correspondingly.

**Table 2.** Bacterial colony numbers at different concentrations of granisetron

Granisetron (mg/mL)	Incubation time (hours)	E. coli (CFU/mL)	S. aureus (CFU/mL)	P. aeruginosa (CFU/mL)
0.5	6	$(3.1 \pm 1.1) \times 10^{4*}$	$(2.8 \pm 0.5) \times 10^{4*}$	$(3.3 \pm 0.2) \times 10^{5*}$
	24	$(6.7 \pm 2.6) \times 10^{2* \#}$	$(7.6 \pm 3.5) \times 10^{3* \#}$	$(5.7 \pm 2.4) \times 10^{4* \#}$
0.25	6	$(9.6 \pm 1.8) \times 10^{4*}$	$(5.5 \pm 1.3) \times 10^{5*}$	$(1.1 \pm 0.7) \times 10^6$
	24	$(2.4 \pm 0.9) \times 10^{3* \#}$	$(1.3 \pm 0.5) \times 10^{4* \#}$	$(8.2 \pm 0.9) \times 10^5$
0.125	6	$(6 \pm 2.1) \times 10^5$	$(8.3 \pm 2.1) \times 10^6$	$(1.3 \pm 0.6) \times 10^6$
	24	$(1.3 \pm 0.6) \times 10^{5* \#}$	$(9.5 \pm 2.3) \times 10^6$	$(4.8 \pm 2.1) \times 10^6$
0.0625	6	$(5.1 \pm 1.3) \times 10^6$	$(5.3 \pm 1.8) \times 10^6$	$(2.7 \pm 0.3) \times 10^6$
	24	$(1.7 \pm 0.7) \times 10^{6*}$	$(1.7 \pm 0.7) \times 10^7$	$(2.3 \pm 0.9) \times 10^6$
0	0		$5 \times 10^6$	
	6	$(1.1 \pm 0.3) \times 10^7$	$(1.0 \pm 0.1) \times 10^7$	$(4.1 \pm 1.1) \times 10^6$
	24	$(1.3 \pm 0.4) \times 10^7$	$(3.9 \pm 0.7) \times 10^7$	$(6.5 \pm 0.6) \times 10^6$

\*P<0.01, versus bacterial cultured with 0 mg/ml for 6 hours or 24 hours correspondingly; #P<0.01, versus bacterial cultured with different drug concentrations for 6 hours correspondingly.

monas aeruginosa (*P. aeruginosa*) (ATCC27853) were obtained from Jiangsu Province Center for Clinical Standards.

### *In vitro* bacteria culture

Bacteria were grown in soybean casein digest medium for 18 hours to reach the exponential growth phase and diluted with sterile saline to reach a McFarland unit. Each McFarland unit corresponds to an initial concentration of about  $3 \times 10^8$  colony forming units (CFU)/mL. Each standard inoculum was diluted using sterile saline and inoculated onto a single blood agar and cultured for 6 hours or 24 hours at 37°C. 20 µL of bacteria containing approximately  $5 \times 10^6$  CFU were added to 980 µL of ondansetron and granisetron solutions at different concentrations, followed by incubation at 37°C. An equal volume of sterile saline was used as con-

trol. After incubation for 24 hours, 100 µL of 1:10,000 bacteria dilution was then inoculated on blood agar medium and cultured at 37°C. Colony numbers were counted after 24 hours. Each experiment was repeated ten times.


### Statistics analysis

All data are presented as mean ± standard deviation (SD). Statistical analyses were performed with the Prism software package (GraphPad v5, San Diego, CA, USA). Data were analyzed using one-way ANOVA. A P-value less than 0.01 was accepted as statistically significant.


### Results

Both ondansetron and granisetron showed significant antimicrobial effect with a time- and dose-dependent manner on *E. coli*, *S. aureus*,


## Andansetron and granisetron as antibacterial




**Figure 1.** Colony counts of *E. coli* after 6 and 24 h incubation with various concentrations of ondansetron. \*Colony count of each group is significantly lower ( $P<0.01$ ) than control. #For each concentration of ondansetron, colony count is significantly different ( $P<0.01$ ) between 24 and 6 h incubation.



**Figure 3.** Colony counts of *P. aeruginosa* after 6 and 24 h incubation with various concentrations of ondansetron. \*Colony count of each group is significantly lower ( $P<0.01$ ) than control. #For each concentration of ondansetron, colony count is significantly different ( $P<0.01$ ) between 24 and 6 h incubation.



**Figure 2.** Colony counts of *S. aureus* after 6 and 24 h incubation with various concentrations of ondansetron. \*Colony count of each group is significantly lower ( $P<0.01$ ) than control. #For each concentration of ondansetron, colony count is significantly different ( $P<0.01$ ) between 24 and 6 h incubation.




**Figure 4.** Colony counts of *E. coli* after 6 and 24 h incubation with various concentrations of granisetron. \*Colony count of each group is significantly lower ( $P<0.01$ ) than control. #For each concentration of ondansetron, colony count is significantly different ( $P<0.01$ ) between 24 and 6 h incubation.

and *P. aeruginosa* (Tables 1, 2 and Figures 1-6).


The concentrations of ondansetron inhibited growth of *E. coli* are higher than 0.25 mg/ml ( $P<0.01$ ) (Table 1; Figure 1). The concentrations of *S. aureus* and *P. aeruginosa* are both higher than 0.5 mg/ml ( $P<0.01$ ) (Table 1; Figures 2, 3), and with The higher concentration, the inhibitive effect on bacterial growth is greater. The concentrations of granisetron in-

hibited bacterial growth are lower than ondansetron. The inhibitory effect started at 0.25 mg/ml for *S. aureus*, and at 0.5 mg/ml for *P. aeruginosa* ( $P<0.01$ ) (Table 2; Figures 5, 6). Granisetron exhibited growth inhibitory effect on *E. coli* even at a concentration of 0.0625 mg/ml after 24 h incubation times ( $P<0.01$ ) (Table 2; Figure 4). Almost in all strains, there was a significant difference in the antibacterial activity between 6 and 24 h incubation times when the concentration of agents inhibited bacterial growth.

## Andansetron and granisetron as antibacterial



**Figure 5.** Colony counts of *S aureus* after 6 and 24 h incubation with various concentrations of ondansetron. \*Colony count of each group is significantly lower ( $P < 0.01$ ) than control. #For each concentration of ondansetron, colony count is significantly different ( $P < 0.01$ ) between 24 and 6 h incubation.



**Figure 6.** Colony counts of *P. aeruginosa* after 6 and 24 h incubation with various concentrations of granisetron. \*Colony count of each group is significantly lower ( $P < 0.01$ ) than control. #For each concentration of ondansetron, colony count is significantly different ( $P < 0.01$ ) between 24 and 6 h incubation.

### Discussion

Although the overall incidence of epidural infection is still relatively low, the infection rate has been on the rise since the application of patient-controlled epidural analgesia (PCEA) [4]. PCEA after surgery commonly used local anesthetic and combines with anti-nausea, anti-vomiting drugs [5]. So the research on whether the analgesic and antiemetic drugs have any antibacterial effect has important clinical sig-

nificance. Previous studies showed that the local anesthetics such as lidocaine and ropivacaine have antibacterial effects, but the antibacterial activities of antiemetic drugs have not been reported. So this study focused on the most common clinical antiemetic drugs, ondansetron and granisetron, to show that they can both inhibit the growth of such bacteria as *E. coli*, *S. aureus*, and *P. aeruginosa* in vitro. *E. coli*, *S. aureus* and *P. aeruginosa* were chosen for the study because they are widely present on the human skin surface, and are commonly used as surveillance targets for hospital infection [7].

PCEA was widely used, especially in obstetrics and gynecology. The PCEA pumps were often filled with ropivacaine (1.5 mg/ml) and ondansetron (160 µg/ml) or granisetron (90 µg/ml) in saline solution and set with a bolus of 2 ml, a lockout interval of 10 min. The ondansetron have not IV administration, so the concentration of ondansetron was higher in epidural space (160 µg/ml) than that in the blood (5 µg/ml) after intravenous injection [13].

The potential mechanism by which ondansetron and granisetron inhibit bacteria growth is unclear. Previous studies have shown that the bacterial inhibitory effect of local anesthetics is due to interference with the function of the prokaryotic cell membranes. Local anesthetics interfered with *E. coli* respiration lead to the outflow of the cell contents [14]. Lidocaine has also been reported to inhibit neutrophil adhesion and chemotaxis. Research has also shown that by changing the permeability of the outer membrane of the bacterial cell, and lidocaine can cause bacterial cell depolarization [15]. Tanji, et al. found that local anesthetics inhibit the intracellular ATP production, meanwhile upregulate heat shock proteins [16]. Whether antiemetics such as ondansetron and granisetron employ similar mechanisms to inhibit bacteria growth requires further study. Bacteria often exist in an extracellular polymeric matrix composed of proteins, polysaccharides and nucleic acids, which confer a physical barrier to diffusion of molecules such as antibiotics. One of the mechanisms of antibiotic resistance is the formation of a large matrix [17, 18]. The higher mRNA level of polysaccharide biosynthesis genes *pspA*, *algD*, *pelA* in *P. Aeruginosa* may contribute to the creation of the matrix [19, 20].

Interestingly, in this study *P. aeruginosa* is also more resistant to ondansetron and granisetron compared to *E. coli*.

In summary, ondansetron and granisetron inhibited the growth of *E. coli*, *S. aureus*, and *P. aeruginosa* growth in the time- and dose-dependent manner in vitro. Moreover, at the concentrations commonly used in practice, ondansetron and granisetron significantly inhibited the growth of *E. coli*, which showing clinical potential for the prevention of anesthesia-related infections.

**Disclosure of conflict of interest**

None.

**Address correspondence to:** Jie Wang, Department of Anesthesiology, Wujiang First Hospital, Nantong University Medical School, Suzhou, P.R. China. E-mail: natalia07@sohu.com

**References**

[1] Yee LM, Sandoval G, Bailit J, Reddy UM, Wapner RJ, Varner MW, Caritis SN, Prasad M, Tita AT, Saade G, Sorokin Y, Rouse DJ, Blackwell SC, Tolosa JE; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Maternal and neonatal outcomes with early compared with delayed pushing among nulliparous women. *Obstet Gynecol* 2016; 128: 1039-47.

[2] Djakovic I, Sabolovic Rudman S, Kosec V. Effect of epidural analgesia on mode of delivery. *Wien Med Wochenschr* 2016; [Epub ahead of print].

[3] Xue X, Song J, Liang Q, Qin J. Bacterial infection in deep paraspinal muscles in a parturient following epidural analgesia: a case report and literature review: a CARE-compliant article. *Medicine (Baltimore)* 2015; 94: e2149.

[4] Chan YC, Dasey N. Iatrogenic spinal epidural abscess. *Acta Chir Belg* 2007; 107: 109-18.

[5] Gan TJ. Risk factors for postoperative nausea and vomiting. *Anesth Analg* 2006; 102: 1884-98.

[6] Sakuragi T, Ishino H, Dan K. Bactericidal activity of preservative-free bupivacaine on microorganisms in the human skin flora. *Acta Anaesthesiol Scand* 1998; 42: 1096-9.

[7] Tamanai-Shacoori Z, Shacoori V, Jolivet-Gougeon A, Vo Van JM, Repère M, Donnio PY, Bonnaure-Mallet M. The antibacterial activity of tramadol against bacteria associated with infectious complications after local or regional anesthesia. *Anesth Analg* 2007; 105: 524-7.

[8] Silva MT, Sousa JC, Polonia JJ, Macedo PM. Effects of local anesthetics on bacterial cells. *J Bacteriol* 1979; 137: 461-8.

[9] Boselli E, Guillier M, Freney J, Mazoyer MA, Casoli E, Renaud FR, Rimmelé T, Chassard D, Allaouchiche B. Antibacterial activity of clonidine and neostigmine in vitro. *Anesth Analg* 2005; 101: 121-4, table of contents.

[10] Tomasik E, Ziolkowska E, Kolodziej M, Szajewska H. Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis. *Aliment Pharmacol Ther* 2016; 44: 438-46.

[11] Dong H, Lu SJ, Zhang R, Liu DD, Zhang YZ, Song CY. Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients. *Eur J Clin Pharmacol* 2015; 71: 681-6.

[12] Coban AY, Tanriverdi Cayci Y, Keles Uludag S, Durupinar B. [Investigation of antibacterial activity of sertraline]. *Mikrobiyol Bul* 2009; 43: 651-6.

[13] VanDenBerg CM, Kazmi Y, Stewart J, Weidler DJ, Tenjarla SN, Ward ES, Jann MW. Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-mg oral tablet, rectal suppository, and i.v. infusion. *Am J Health Syst Pharm* 2000; 57: 1046-50.

[14] Ohsuka S, Ohta M, Masuda K, Arakawa Y, Kaneda T, Kato N. Lidocaine hydrochloride and acetylsalicylate kill bacteria by disrupting the bacterial membrane potential in different ways. *Microbiol Immunol* 1994; 38: 429-34.

[15] Lazdunski C, Baty D, Pages JM. Procaine, a local anesthetic interacting with the cell membrane, inhibits the processing of precursor forms of periplasmic proteins in *Escherichia coli*. *Eur J Biochem* 1979; 96: 49-57.

[16] Tanji K, Mizushima T, Natori S, Sekimizu K. Induction by psychotropic drugs and local anesthetics of DnaK and GroEL proteins in *Escherichia coli*. *Biochim Biophys Acta* 1992; 1129: 172-6.

[17] Chandan SS, Faoagali J, Wainwright CE. Sensitivity of respiratory bacteria to lignocaine. *Pathology* 2005; 37: 305-7.

[18] Ryder C, Byrd M, Wozniak DJ. Role of polysaccharides in *Pseudomonas aeruginosa* biofilm development. *Curr Opin Microbiol* 2007; 10: 644-8.

[19] Ghafoor A, Jordens Z, Rehm BH. Role of pelf in pel polysaccharide biosynthesis in *Pseudomonas aeruginosa*. *Appl Environ Microbiol* 2013; 79: 2968-78.

[20] Li LY, Wei DJ, Men K, Wu DW and Chen JY. Research of polysaccharide biosynthesis-related gene expression in *Pseudomonas aeruginosa*. *Chinese Journal of Microbiology and Immunology* 2009; 29: 513-516.